The 10 most expensive prescription medications in the US
After Monday’s announcement of President Donald Trump of an executive order that will reduce the prices of prescribed medications in the US, the center of attention is in current costs and how much Americans could save.
The president’s order requires “most favored drug prices of nations”, which means “the lowest price paid by a medicine in other developed countries, that is the price that Americans will pay,” he said.
“Some prices of prescription and pharmaceutical drugs will be reduced almost immediately between 50 and 80%,” Trump said.
President Trump assumes ‘Big Pharma’ signing the executive order to reduce medicines prices
Katy Dubinsky, Pharmaceutical of New York and founder and executive director of Vitalize, applauded the movement to reduce recipe prices, noting that Trump’s order addresses a long -standing problem.
“But this will not be easy to achieve,” he told News Digital.
After the announcement of President Trump of an executive order that will reduce the prices of prescribed medications in the United States, the center of attention is in current costs and how much Americans could save. (Istock)
“The executive order does not reduce costs immediately,” he said. “He directs government agencies to write the rules, which can take months.”
These are the five most expensive medications in the US. UU. For price, followed by five per volume.
5 most expensive prescription medications in the United States
Dubinsky detailed some of the most expensive prescription medications in the country today and what conditions they deal with.
1. Lenmeldy (Atidarsagene Autotemcel) by Orchard Therapeutics – $ 4.25 million
This medicine is used to treat metacromatic leukodystrophy (MLD), a rare genetic disorder that damages the nervous system, said Dubinsky.
“It is administered once and it is supposed to stop or slow down the disease in young children,” he said.
TOP 10 ‘ALERGY CAPITALS’ of the US
2. HEMGENIX (Etranacogene dezaparvovec-Drlb) per csl behring- $ 3.5 million
This medicine is prescribed for people with hemophilia B, a hemorrhagic disorder.
“This unique treatment helps the body to make its own coagulation factor, so patients do not need regular infusions,” Dubinsky said.
3. Elevidys (Deandistagene Moxparvovec-Rokl) by Sarepta Therapeutics- $ 3.2 million
This prescribed medication, intended for young children, treats Duchenne’s muscular dystrophy (DMD), a condition that weakens muscles over time.
“His goal is to slow down how quickly the disease progresses,” Dubinsky said.
The president’s order demands “most favored drug prices of nations”, which means “the lowest price paid by a medicine in other developed countries, that is the price that Americans will pay.” (Istock)
4. Skysona (Eliveldagene Autotemcel) of Bluebird Bio – $ 3 million
“This medicine is used for adrenoleukodystrophy cerebral (Cald), a severe brain disease in children,” Dubinsky said. “This therapy tries to delay damage before symptoms get worse.”
5. ZYNTEGLO (Betibeglogene Autotemcel) of Bluebird Bio – $ 2.8 million
Zynteglo is for beta-caasmia, a blood condition that generally requires regular transfusions.
“Some prices of prescription and pharmaceutical drugs will be reduced almost immediately between 50 and 80%.”
“This gene therapy can help patients do healthy red blood cells on their own and reduce the frequency with which they need treatment,” Dubinsky said.
The 5 most expensive drugs per sales volume
John Stanford, Executive Director of Incubate, a coalition based in Washington of Life Science Investors in the early stage, shared his thoughts about the five most expensive drugs per sales volume.
“Usually, when the government focuses on the most expensive medications, they focus on the metric depending on the volume of sales instead of, for example, rare disease therapy with a high list price but a smaller group of patients,” said News Digital.
“Often, officials focus on the total drug spending by Medicare or other government programs.”
“Usually, when the government focuses on the most expensive medications, they focus on the metric depending on the sales volume instead of, for example, rare disease therapy with a high list price but a smaller group of patients.” (Istock)
1. Keytruda (Pmbrolizumab) per merk – Income of $ 25 billion (2023)
Keytruda is an immunotherapy medication used to treat a variety of cancers, which include melanoma, lung cancer of non -small cells, liver cancer and others.
“Keytruda has become the jewel of Merck’s crown, helping the company expand its cancer treatment portfolio with more than 1,000 active clinical trials,” Stanford told News Digital.
Terminal colon cancer patient saved by innovative treatment
2. Eliquis (Apixaban) by Bristol Myers Squibb and Pfizer – $ 18.95 billion
Eliquis (Apixaban) is a “anchor drug” for both BMS and Pfizer, according to Stanford.
The Apixaban is prescribed to prevent the formation of blood clots and to treat deep venous thrombosis and pulmonary embolism (a blood clot in the lungs).
3. Ozempic (Semaglutide) by Novo Nordisk – $ 13.93 billion
Prescribed for type 2 diabetes, the Ozempic of Semaglutida medication has become widely popular because of its weight loss effects and other health benefits.
Prescribed for type 2 diabetes, the Ozempic of Semaglutida medication has become widely popular because of its weight loss effects and other health benefits. (Reuters/Hollie Adams/File Photo)
“Ozempic sales are promoting the broader incursion of Novo Nordisk in LPG-1 due to obesity, heart disease and liver conditions, all areas with high development costs and uncertain scientific results,” Stanford told News Digital.
“Money has been destined to expand production to meet the demand for LPG-1 and avoid the shortage of supply.”
4. Humira (ABBVIE) – $ 14.4 billion (US 2023 income)
“Humira has been one of the highest grossing drugs in history, generating more than $ 200 billion during its exclusivity period,” Stanford said.
The injectable medicine, which contains the active adalimumab ingredient, is used to treat rheumatoid arthritis and other inflammatory conditions.
Click here to register in our health newsletter
5. Gilead Biktarvy – $ 11.85 billion
Biktarvy is an HIV treatment that includes the three bike, emptorchravir and tenofovir allafenamide ingredients.
“Biktarvy is not just a leading HIV treatment, it is the financial spine for Gilead’s transfer to cancer investigation,” Stanford said.
What drugs could be affected?
Dr. Jacob Glanville, CEO of Centivax, a biotechnology company in San Francisco, said that vaccines and most generic medications would probably not be changed by the executive order.
“Most vaccines taken by Americans cost less than one hundred dollars, while generic drugs are often less than one dollar per pill,” he told News Digital.
“From the perspective of a patient, the price of medical care in the United States is unsustainable, and extremely expensive medicine is part of that,” said an expert. “However, the hospital insurance and business also contributes.” (Istock)
What would be affected, predicted Glanville, are newer brands that are still under exclusive IP, antibody therapies, cell therapies, gene therapies and personalized cancer vaccines.
“Some of these are unbearably expensive: $ 100,000 to $ 500,000 for a treatment course for a patient. However, they are also often the most effective treatments for certain cancers, autoimmune disorders or rare diseases.”
The price of innovation?
The pharmaceutical industry could argue that reducing prices in these medications will result in a “dramatic investment reduction” in the creation of such advances, Glanville said.
The industry can also argue that these medications eventually become generic, at which time prices fall, according to the expert.
For more health articles, visit www.Newsnews.com/health
“From the perspective of a patient, the price of medical care in the United States is unsustainable, and extremely expensive medicine is part of that,” he said. But “the hospital insurance and business system also contributes.”
“If the prices of the new medications are limited, then an effort must be made to reduce the cost of clinical trials and the manufacture of medicines. Otherwise, we will lose a lot of innovation.”
Click here to get the News application
Greg Norman of News Digital contributed reports.
Melissa Rudy is a senior health editor and a member of the lifestyle in News Digital. The advice of history can be sent to melissa.rudy@News.com.